SPARTA Doublet: A Phase 2, Randomized, Double-Blind (Subject- and Investigator-Blind, Sponsor-Open), Placebo-Controlled Trial to Investigate the Safety, Tolerability, and Efficacy of ACH-0143422 in Combination withACH-0143102 for 12, 8, or 6 Weeks in Treatment-Naive Subjects with Chronic Hepatitis C

Trial Profile

SPARTA Doublet: A Phase 2, Randomized, Double-Blind (Subject- and Investigator-Blind, Sponsor-Open), Placebo-Controlled Trial to Investigate the Safety, Tolerability, and Efficacy of ACH-0143422 in Combination withACH-0143102 for 12, 8, or 6 Weeks in Treatment-Naive Subjects with Chronic Hepatitis C

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs ACH 3422 (Primary) ; Odalasvir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPARTA Doublet
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 12 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top